| Literature DB >> 16704784 |
Larissa Grigoryan1, Flora M Haaijer-Ruskamp, Johannes G M Burgerhof, Reli Mechtler, Reginald Deschepper, Arjana Tambic-Andrasevic, Retnosari Andrajati, Dominique L Monnet, Robert Cunney, Antonella Di Matteo, Hana Edelsein, Rolanda Valinteliene, Alaa Alkerwi, Elizabeth Scicluna, Powel Grzesiowski, Ana-Claudia Bara, Thomas Tesar, Milan Cizman, Jose Campos, Cecilia Stålsby Lundborg, Joan Birkin.
Abstract
We surveyed the populations of 19 European countries to compare the prevalence of antimicrobial drug self-medication in the previous 12 months and intended self-medication and storage and to identify the associated demographic characteristics. By using a multistage sampling design, 1,000-3,000 adults in each country were randomly selected. The prevalence of actual self-medication varied from 1 to 210 per 1,000 and intended self-medication from 73 to 449 per 1,000; both rates were high in eastern and southern Europe and low in northern and western Europe. The most common reasons for self-medication were throat symptoms (e.g., dry, inflamed, red, or sore throat, inflamed tonsils, tonsil pain). The main medication sources were pharmacies and medication leftover from previous prescriptions. Younger age, higher education, and presence of a chronic disease were associated with higher rates of self-medication. Attempts to reduce inappropriate self-medication should target prescribers, pharmacists, and the general public.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16704784 PMCID: PMC3291450 DOI: 10.3201/eid1203.050992
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
General characteristics of respondents in each European country
| Country | Response rate (%) | No. respondents | Mean age (y) ± SD | Female (%) | Low education level* (%) | Presence of chronic disease (%)† | Urban location (%) |
|---|---|---|---|---|---|---|---|
| Northern and western | |||||||
| The Netherlands | 55 | 1,634 | 48 ± 17 | 58 | 30 | 15 | 48 |
| Sweden | 69 | 704 | 54 ± 19 | 53 | 53 | 14 | 49 |
| Denmark | 63 | 1,881 | 48 ± 17 | 56 | 60 | 14 | 49 |
| Austria | 28 | 442 | 49 ± 16 | 50 | 64 | 15 | 53 |
| Belgium | 54 | 1,734 | 45 ± 16 | 55 | 32 | 13 | 50 |
| Luxembourg | 50 | 675 | 46 ± 18 | 51 | 49 | 15 | 45 |
| United Kingdom‡ | 23 | 675 | 50 ± 10 | 58 | 40 | 15 | 58 |
| Ireland | 26 | 793 | 48 ± 16 | 59 | 53 | 17 | 47 |
| Southern | |||||||
| Israel | 18 | 467 | 50 ± 17 | 61 | 19 | 22 | 36 |
| Malta | 54 | 541 | 46 ± 16 | 55 | 60 | 21 | 47 |
| Italy | 21 | 213 | 45 ± 18 | 61 | 37 | 27 | 51 |
| Spain | 20 | 204 | 47 ± 14 | 47 | 31 | 18 | 57 |
| Eastern | |||||||
| Czech Republic | 59 | 1,169 | 54 ± 15 | 36 | 45 | 27 | 48 |
| Slovenia | 38 | 1,143 | 48 ± 17 | 58 | 70 | 20 | 47 |
| Croatia | 31 | 615 | 53 ± 16 | 55 | 10 | 26 | 58 |
| Poland | 32 | 935 | 45 ± 18 | 60 | 42 | 23 | 52 |
| Slovakia | 55 | 546 | 41 ± 16 | 54 | 27 | 23 | 54 |
| Romania | 43 | 430 | 50 ± 18 | 49 | 43 | 27 | 43 |
| Lithuania | 25 | 747 | 59 ± 18 | 35 | 32 | 39 | 54 |
*Low education level was defined as incomplete primary education, completed primary education, and lower vocational or general education. †Including any of the following diseases: asthma, chronic bronchitis, emphysema, human immunodeficiency virus infection, cystic fibrosis, diabetes, endocarditis, tuberculosis, prostatitis, chronic urinary tract infection, chronic osteomyelitis, peptic ulcer disease, chronic pyelonephritis or cancer. ‡Reminders were not sent to nonrespondents.
Actual use of systemic antimicrobial drugs in the last 12 months and at-risk self-medication in 19 European countries
| Country (region in country) | Rate per 1,000 respondents (95% confidence interval) | |||||
|---|---|---|---|---|---|---|
| Actual self-medication | Prescribed use | Intended self-medication | Storage* (conservative estimate) | Storage† (maximum estimate) | ||
| Countries with response rate >40% | ||||||
| Northern and western | ||||||
| The Netherlands (Twente) | 1 (0.2–4) | 152 (134–170) | 85 (71–101) | 10 (6–17) | 36 (28–46) | |
| Sweden (Vastmanland) | 4 (0.9–12) | 135 (109–161) | 118 (94–143) | 14 (7–26) | 43 (29–60) | |
| Denmark (Funen, Aarhus, Copenhagen‡) | 7 (4–12) | 172 (154–189) | 132 (116–147) | 42 (33–52) | 84 (72–97) | |
| Luxemburg (whole country) | 9 (3–19) | 288 (252–324) | 83 (62–107) | 90 (69–114) | 132 (106–158) | |
| Belgium (East Flanders, Flemish Brabant) | 9 (5–15) | 222 (201–242) | 80 (67–95) | 71 (59–84) | 123 (107–138) | |
| Southern | ||||||
| Malta (whole country) | 56 (38–79) | 422 (380–465) | 228 (192–264) | 156 (125–186) | 269 (232–306) | |
| Eastern | ||||||
| Czech Republic (Hradec Krlov) | 7 (3–13) | 253 (228–279) | 179 (156–201) | 45 (33–58) | 64 (51–80) | |
| Slovakia (Middle Slovakia region) | 42 (27–63) | 569 (527–612) | 324 (284–365) | 192 (159–225) | 302 (263–340) | |
| Romania (Dolj) | 198 (160–235) | 307 (263–351) | 431 (383–478) | 200 (162–238) | 321 (277–365) | |
| Countries with response rate <40%§ | ||||||
| Northern and western | 52 (33–77) | |||||
| Austria (Upper Austria) | 9 (2–23) | 159 (124–195) | 73 (49–103) | 34 (19–55) | 52 (33–77) | |
| United Kingdom (Nottinghamshire) | 12 (5–23) | 221 (189–254) | 166 (137–195) | 33 (21–49) | 74 (56–97) | |
| Ireland (Cork) | 14 (7–25) | 353 (320–386) | 150 (125–176) | 29 (19–43) | 100 (80–123) | |
| Southern | ||||||
| Israel (Northern Israel) | 15 (6–31) | 330 (287–374) | 187 (150–223) | 120 (91–149) | 236 (197–274) | |
| Italy (Abruzzo) | 62 (33–103) | 512 (444–580) | 243 (185–301) | 379 (314–445) | 569 (502–636) | |
| Spain (autonomous community of Madrid) | 152 (103–201) | 315 (251–379) | 314 (249–380) | 260 (200–320) | 500 (431–569) | |
| Eastern | ||||||
| Slovenia (Ljubljana region) | 17 (10–26) | 293 (266–320) | 280 (253–307) | 119 (100–137) | 183 (160–205) | |
| Croatia (Zagreb county) | 31 (19–48) | 439 (399–478) | 205 (172–237) | 130 (103–156) | 212 (179–244) | |
| Poland (Pomorskie) | 33 (23–47) | 199 (172–225) | 115 (94–136) | 69 (53–87) | 137 (115–160) | |
| Lithuania (Klaipeda, Rietavas) | 210 (181–239) | 275 (243–308) | 449 (412–486) | 177 (149–204) | 333 (299–367) | |
*Included only those respondents who stored antimicrobial drugs and had not taken the same antimicrobial drugs for a prescribed course in the previous 12 months. †Including all respondents who stored antimicrobial drugs. ‡Although Copenhagen has population >750,000, both self-medication and prescribed use of antimicrobial drugs were not significantly different between the sample of Copenhagen and sample of the other 2 Danish counties (χ2 tests). §The rates for these countries should be interpreted as first rough estimates.
Figure A1Use of major groups of antimicrobial drugs for actual self-medication in 17 countries; countries reporting less than 5 self-medication courses are excluded. DK, Denmark; CZ, Czech Republic; LU, Luxembourg ; BE, Belgium; SK, Slovakia; MT, Malta; RO, Romania; AT, Austria; UK, United Kingdom; IL, Israel; IE, Ireland; SI, Slovenia; PL, Poland; HR, Croatia; IT, Italy; ES, Spain; and LT, Lithuania. **Number of courses (taken in the previous 12 months) per 1,000 respondents per country. †Includes systemic amphenicols (J01B), aminoglycosides (J01G), combinations of systemic antibiotics (J01R) and other systemic antibiotics (J01X).
Figure 1Prevalence of actual self-medication by symptoms or diseases classified by International Classification of Primary Care codes (rates pre 1,000 respondents and 95% confidence iinterval). *Symptoms or diseases with rates <1 per 1,000 respondents, including eye infection, pain, prostatitis, urogenital infection, headache, and "bad health."
Figure 2Prevalence of intended self-medication per predefined symptom (rates per 1,000 respondents and 95% confidence interval).
Effects of individual characteristics on actual and at-risk antimicrobial drug self-medication*
| Characteristics | Adjusted odds ratio (95% confidence interval) | |||
|---|---|---|---|---|
| Actual self-medication | Storage (conservative estimate) | Intended self-medication | ||
| Age | 0.985 (0.979–0.992) | 0.977 (0.973–0.982) | 0.984 (0.980–0.987) | |
| Region in Europe† | ||||
| Northern and western | 1 (reference) | 1 | 1 | |
| Southern | 6.776 (4.752–9.662) | 5.101 (4.240–6.137) | 2.233 (1.909–2.613) | |
| Eastern | 7.529 (5.676–9.985) | 3.311 (2.868–3.822) | 2.851 (2.577–3.154) | |
| Education level | ||||
| Low‡ | 1 (reference) | 1 | 1 | |
| High | 1.357 (1.095–1.680) | 1.690 (1.470–1.943) | 1.233 (1.116–1.361) | |
| Chronic disease§ | ||||
| No | 1 (reference) | 1 | 1 | |
| Any | 1.888 (1.497–2.383) | 1.225 (1.038–1.446) | 2.320(1.594–3.378) | |
| Age × any chronic disease | 0.989 (0.982–0.996) | |||
| Exponential (constant) | 0.012 | 0.083 | 0.219 | |
*At-risk self-medication included intended self-medication or storage of drugs at home. †Northern and western includes Sweden, Denmark, the Netherlands, Austria, Belgium, Luxemburg, United Kingdom, Ireland; southern includes Israel, Malta, Italy, and Spain; eastern includes Czech Republic, Slovenia, Croatia, Poland, Slovakia, Romania, and Lithuania. ‡Low education level was defined as incomplete primary education, completed primary education, and lower vocational or general education. §Including any of the following diseases: asthma, chronic bronchitis, emphysema, HIV infection, cystic fibrosis, diabetes, endocarditis, tuberculosis, prostatitis, chronic urinary tract infection, chronic osteomyelitis, peptic ulcer disease, chronic pyelonephritis, or cancer.